1 |
Dexdor |
- |
- |
- |
- |
002 [4] 2 , 4 , 6 , 70 💬 |
2 |
Dexmedetomidine |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 [12] 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
3 |
Dexmedetomidine 1 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
4 |
Dexmedetomidine 2 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
5 |
Dexmedetomidine 3 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
6 |
Dexmedetomidine group |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
7 |
Dexmedetomidine hydrochloride |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
8 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
9 |
Dexmedetomidine with ropivacaine |
Dexmedetomidine |
[4] D00514 D00514, D01205 D01205, D04048 D04048, D08490 D08490 💬 |
ADRA2A [8] ADRA2A, ADRA2B, ADRA2C, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [5] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
10 |
Fentanyl (low dose) + dexmedetomidine |
Dexmedetomidine |
[4] D00320 D00320, D00514 D00514, D01205 D01205, D01399 D01399 💬 |
ADRA2A [4] ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 |
Estrogen signaling pathway [4] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
215 [1] 215 💬 |
11 |
Scopolamine, atropine, edaravone and dexmedetomidine |
Atropine |
[9] D00113 D00113, D00138 D00138, D00514 D00514, D01077 D01077, D01205 D01205, D01552 D01552, D02069 D02069, D03011 D03011, D03814 D03814 💬 |
ADRA2A [8] ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease [14] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
002 [1] 2 💬 |